Literature DB >> 17018888

Focal radiation therapy of brain metastases after complete surgical resection.

Gautam Bahl1, Greg White, John Alksne, Lakshmi Vemuri, Matthew A Spear.   

Abstract

Brain metastases are a frequent occurrence in cancer patients and result in significant morbidity and mortality. The three main treatments for brain metastases include surgery, radiation, and/or chemotherapy, alone or in combination. After resection alone, local recurrence rates are high. Whole brain radiation therapy can decrease the probability of recurrence; however, this has some disadvantages. Focal radiation therapy (FRT) may provide many of the same benefits without some of these disadvantages. In this study, we retrospectively analyzed patients with single brain metastases treated with FRT after surgery. Doses ranged from 14 Gy as single dose stereotactic radiosurgery (SRS) to 54 Gy in 27 2-Gy fractions as conformal fractionated radiotherapy. Four of the seven patients had a same-site recurrence, with an average time to recurrence of 115.5 d. Median dose in the patients that had same-site recurrence was 42 Gy. One of these patients is currently living. Two patients did not have recurrence, and one patient had a recurrence at a different site within the brain. The low rate of out-of-field recurrences during the patients life indicates focal radiation may be a reasonable therapeutic alternative. Given the number of patients with same-site recurrences, wide field margins around the tumor volume or higher radiation doses than those typically used in palliative regimens may be useful in post-excisional FRT. Additionally, we found that a longer delay in the initiation of FRT after initial diagnosis may result in a decreased time to same-site recurrence. However, further studies are warranted given the small number of patients in this study.

Entities:  

Mesh:

Year:  2006        PMID: 17018888     DOI: 10.1385/MO:23:3:317

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  27 in total

1.  Radiosurgery followed by planned observation in patients with one to three brain metastases.

Authors:  Johannes Lutterbach; Donatus Cyron; Karl Henne; Christoph B Ostertag
Journal:  Neurosurgery       Date:  2003-05       Impact factor: 4.654

Review 2.  Medical management of cerebral metastases.

Authors:  T Batchelor; L M DeAngelis
Journal:  Neurosurg Clin N Am       Date:  1996-07       Impact factor: 2.509

3.  The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model.

Authors:  P J Muller; C H Tator; M Bloom
Journal:  J Neurosurg       Date:  1980-03       Impact factor: 5.115

Review 4.  Therapeutic management of brain metastasis.

Authors:  Evert C A Kaal; Charles G J H Niël; Charles J Vecht
Journal:  Lancet Neurol       Date:  2005-05       Impact factor: 44.182

5.  Comparison between observation policy and fractionated stereotactic radiotherapy (SRT) as an initial management for vestibular schwannoma.

Authors:  H Shirato; T Sakamoto; Y Sawamura; K Kagei; T Isu; T Kato; S Fukuda; K Suzuki; S Soma; Y Inuyama; K Miyasaka
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-06-01       Impact factor: 7.038

Review 6.  Epilepsy and brain tumors: implications for treatment.

Authors:  G D Cascino
Journal:  Epilepsia       Date:  1990       Impact factor: 5.864

7.  Resection for solitary brain metastasis. Role of adjuvant radiation and prognostic variables in 229 patients.

Authors:  S R Smalley; E R Laws; J R O'Fallon; E G Shaw; M F Schray
Journal:  J Neurosurg       Date:  1992-10       Impact factor: 5.115

8.  Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Rikiya Onimaru; Kenji Kagei; Jun Ikeda; Nobuaki Ishii; Yutaka Sawamura; Kazuo Miyasaka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-01       Impact factor: 7.038

9.  The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age.

Authors:  E M Noordijk; C J Vecht; H Haaxma-Reiche; G W Padberg; J H Voormolen; F H Hoekstra; J T Tans; N Lambooij; J A Metsaars; A R Wattendorff
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-07-01       Impact factor: 7.038

10.  Surgical management of cerebral metastases from non-small cell lung cancer.

Authors:  Angelos K Koutras; Markos Marangos; Theodoros Kourelis; Melpomeni Partheni; Dimitrios Dougenis; Gregoris Iconomou; Apostolos G Vagenakis; Haralabos P Kalofonos
Journal:  Tumori       Date:  2003 May-Jun
View more
  5 in total

1.  When serendipity meets creativity.

Authors:  Masaaki Yamamoto
Journal:  J Radiosurg SBRT       Date:  2011

2.  Stereotactic Radiosurgery to Prevent Local Recurrence of Brain Metastasis After Surgery: Neoadjuvant Versus Adjuvant.

Authors:  Ian E McCutcheon
Journal:  Acta Neurochir Suppl       Date:  2021

3.  Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline.

Authors:  May N Tsao; Dirk Rades; Andrew Wirth; Simon S Lo; Brita L Danielson; Laurie E Gaspar; Paul W Sperduto; Michael A Vogelbaum; Jeffrey D Radawski; Jian Z Wang; Michael T Gillin; Najeeb Mohideen; Carol A Hahn; Eric L Chang
Journal:  Pract Radiat Oncol       Date:  2012-01-30

4.  Hematopoietic Stem Cell Gene Therapy for Brain Metastases Using Myeloid Cell-Specific Gene Promoters.

Authors:  Tereza Andreou; Nora Rippaus; Krzysztof Wronski; Jennifer Williams; David Taggart; Stephanie Cherqui; Ashley Sunderland; Yolanda D Kartika; Teklu Egnuni; Rebecca J Brownlie; Ryan K Mathew; Sheri L Holmen; Christopher Fife; Alastair Droop; Mihaela Lorger
Journal:  J Natl Cancer Inst       Date:  2020-06-01       Impact factor: 13.506

Review 5.  Modern management for brain metastasis patients using stereotactic radiosurgery: literature review and the authors' gamma knife treatment experiences.

Authors:  Yoshinori Higuchi; Masaaki Yamamoto; Toru Serizawa; Hitoshi Aiyama; Yasunori Sato; Bierta E Barfod
Journal:  Cancer Manag Res       Date:  2018-07-05       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.